"On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue SUPPL. 5, 2006, Pages

  Goh, Khean Lee ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Gastroesophageal reflux disease; On demand therapy; Proton pump inhibitors

Indexed keywords

ANTIHISTAMINIC AGENT; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; RELAPSE; REVIEW; VISUAL ANALOG SCALE;

EID: 33750895875     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04714.x     Document Type: Review

References (36)

1. Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44: 1-16.
2. Tytgat GNJ. Long-term therapy for reflux esophagitis. N. Engl. J. Med. 1995; 333: 1148-50.
3. Kinkenberg EC, Festen H, Jansen J et al. Long term treatment with omeprazole for refractory reflux oesophagitis: efficacy and safety. Ann. Intern. Med. 1994; 121: 161-7.
4. Marks RD, Richter JE, Rizzo J et al. Omeprazole vs H2 antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15.
5. Smith PM, Kerr GD, Cockel R et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 1312-18.
6. Carlson R, Dent Jewett's R et al. Gastro-oesophageal reflux disease (GORD) in primary care - an international study of different treatment strategies with omeprazole. Eur. J. Gastroenterol. Hepatol. 1998; 10: 119-24.
7. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1995; 9: 271-80.675-81.
8. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1995; 9 (Suppl 1): 9-14.
9. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance of oral H2-receptor antagonists. Dig. Dis. Sci. 1990; 35: 976-83.
10. Wilder-Smith CH, Halter F, Ernst T et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment. Pharmacol. Ther. 1990; 4 (Suppl 1): 15-27.
11. Wilder-Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists. An overview. Scand. J. Gastroenterol. 1992; 27 (Suppl 193): 14-19.
12. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. 1995; 333: 1106-10.
13. Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment. Pharmacol. Ther. 1997; 11: 473-82.
14. Bieszk N, Kale-Pradhan PB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann. Pharmacother. 1999; 33: 638-41.
15. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and 'on-demand' therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment. Pharmacol. Ther. 2005; 21: 1299-312.
16. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br. J. Gen. Pract. 1999; 49: 463-4.
17. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br. J. Gen. Pract. 1999; 49: 451-3.
18. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-46.
19. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-89.
20. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment. Pharmacol. Ther. 2002; 16: 1301-7.
21. Ohning GV, Walsh JH, Pisegna JR et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment. Pharmacol. Ther. 2003; 17: 1109-14.
22. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 2003; 17: 1-8.
23. Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, the European Rabeprazole Study Group. Double-blind comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1999; 13: 49-57.
24. Delchier J-C, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 2000; 35: 1245-50.
25. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, for the FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 2002; 16: 445-54.
26. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol. 2002; 97: 1332-9.
27. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 479-85.
28. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment. Pharmacol. Ther. 1999; 13: 907-14.
29. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. 2001; 15: 347-54.
30. Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of 'on-demand' therapy for 6 months. Eur. J. Gastroenterol. Hepatol. 2002; 14: 857-63.
31. Bytzer P, Blum A, De Herdt D, Dubois D. The Trial Investigators. Six-month trial of 'on-demand' rabeprazole 10 mg maintains symptom relief in patients with nonerosive reflux disease. Aliment. Pharmacol. Ther. 2004; 20: 181-8.
32. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. 'On-demand' treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand. J. Gastroenterol. 2002; 37: 642-7.
33. Shotten T, Dekkers CP, Schutze K, Korner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005; 72: 76-85.
34. Bour B, Staub JL, Chousterman M et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: 'on-demand' treatment compared with continuous treatment. Aliment. Pharmacol. Ther. 2005; 21: 805-12.
35. Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. 'On-demand' therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig. Dis. Sci. 2004; 49: 931-6.
36. Goh KL, Chang CS, Fock KM, Ke M, Park HJ, Lam SK. Gastrooesophageal reflux disease in Asia. J. Gastroenterol. Hepatol. 2000; 15: 230-8.